Compare Crispr Therapeutics AG (CRSP) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Trade Desk Inc — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while Trade Desk Inc trades at $19.03 (market cap $8.90B). The key difference: Trade Desk Inc is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | TTD | |
|---|---|---|
Market Cap | $4.97B | $8.90B |
Sector | Health | Technology |
52-Week High | $76.78 | $89.76 |
52-Week Low | $44.34 | $17.33 |
Enterprise Value | $3.32B | $7.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
The Trade Desk (TTD) trades at $19.79, up 1.33% with a mixed technical picture showing bullish overall signals but bearish moving averages. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though revenue growth has slowed from 25% to 12% guidance. Recent developments include new data partnerships in Japan and board appointments, while settling the Publicis dispute removes a key headwind.
TTD presents a value opportunity trading below consensus targets with strong cash flow generation, but faces growth deceleration and competitive pressures. The stock's 52% decline year-to-date reflects market concerns about market share loss to walled gardens, though aggressive share repurchases and attractive valuation multiples support potential upside if growth stabilizes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
